WallStSmart

IDEXX Laboratories Inc (IDXX)vsTwist Bioscience Corp (TWST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IDEXX Laboratories Inc generates 999% more annual revenue ($4.30B vs $391.56M). IDXX leads profitability with a 24.6% profit margin vs -19.6%. IDXX earns a higher WallStSmart Score of 61/100 (C+).

IDXX

Buy

61

out of 100

Grade: C+

Growth: 6.7Profit: 9.5Value: 4.7Quality: 5.0
Piotroski: 5/9

TWST

Avoid

28

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 5.8
Piotroski: 4/9Altman Z: -0.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IDXXSignificantly Overvalued (-40.2%)

Margin of Safety

-40.2%

Fair Value

$462.85

Current Price

$575.72

$112.87 premium

UndervaluedFair: $462.85Overvalued

Intrinsic value data unavailable for TWST.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IDXX3 strengths · Avg: 9.0/10
Return on EquityProfitability
66.2%10/10

Every $100 of equity generates 66 in profit

Profit MarginProfitability
24.6%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

TWST1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
16.9%8/10

16.9% revenue growth

Areas to Watch

IDXX3 concerns · Avg: 2.0/10
PEG RatioValuation
3.972/10

Expensive relative to growth rate

P/E RatioValuation
43.7x2/10

Premium valuation, high expectations priced in

Price/BookValuation
28.6x2/10

Trading at 28.6x book value

TWST4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-16.8%2/10

ROE of -16.8% — below average capital efficiency

Free Cash FlowQuality
$-34.79M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
-0.562/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 24.6% and operating margin at 29.8%. Revenue growth of 14.3% demonstrates continued momentum.

Bull Case : TWST

The strongest argument for TWST centers on Revenue Growth. Revenue growth of 16.9% demonstrates continued momentum.

Bear Case : IDXX

The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 43.7x leaves little room for execution misses.

Bear Case : TWST

The primary concerns for TWST are EPS Growth, Return on Equity, Free Cash Flow.

Key Dynamics to Monitor

IDXX profiles as a mature stock while TWST is a growth play — different risk/reward profiles.

TWST carries more volatility with a beta of 2.29 — expect wider price swings.

TWST is growing revenue faster at 16.9% — sustainability is the question.

IDXX generates stronger free cash flow (323M), providing more financial flexibility.

Bottom Line

IDXX scores higher overall (61/100 vs 28/100), backed by strong 24.6% margins and 14.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Twist Bioscience Corp

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.

Want to dig deeper into these stocks?